A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-Induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2010
At a glance
- Drugs Cobiprostone (Primary)
- Indications NSAID-induced gastrointestinal damage
- Focus Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 02 Jun 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 03 May 2010 Results have been presented at DDW 2010.
- 02 Jul 2009 Top-line results presented in a Sucampo Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History